By Federation of European Academies of Medicine
21 November 2019 saw the launch of a new MEP Interest Group on Antimicrobial Resistance (AMR) to help address this global health threat under a multi-sectoral ‘One Health’ approach integrating its human, animal, and environmental components.
Quick tests for bacterial infections are out there, but insurers won’t cover them and doctors are reluctant to use them.
Researchers from ENABLE are hopeful about apramycin because it has passed the stage at which most potential antibiotics fail.
The results presented in this report are based on antimicrobial resistance (AMR) data from invasive isolates reported to the European Antimicrobial Resistance Surveillance Network (EARS-Net) by 30 European Union (EU) and European Economic Area (EEA) countries in 2019 (data referring to 2018), and on trend analyses of data reported by the participating countries for the period 2015 to 2018.
There’s no lack of chemicals that can kill bacteria. One of the main reasons there have been so few new antibiotics developed in recent decades – apart from a poor return on investment – is that researchers have run out of ideas on how to outwit the protective mechanisms of Gram-negative bacteria.
Statement by EU chief for Health and Food Safety, Vytenis Andriukaitis & Japanese Minister for Health, Labour and Welfare, Kato Katsunobu on “Superbugs: last call for action”.
The European Union (EU) produced antibiotics worth €2 970 million in 2018. Italy was the EU’s biggest producer of antibiotics, accounting for over a third of all antibiotics produced in the EU in 2018 (€1 020 million worth of antibiotics, 34% of the EU total).